CDNA
CareDx, Inc. Healthcare - Diagnostics & Research Investor Relations →
CareDx, Inc. (CDNA) closed at $17.15 as of 2026-03-20, trading 8.1% above its 200-week moving average of $15.87. The stock moved further from the line this week, up from 6.9% last week. The 14-week RSI sits at 34, indicating neutral momentum.
Trading volume is running at 1.2x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.92 ratio) is neutral — neither side is clearly dominating.
Over the past 561 weeks of data, CDNA has crossed below its 200-week moving average 5 times. On average, these episodes lasted 63 weeks. The average one-year return after crossing below was -46.3%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $882 million, CDNA is a small-cap stock. The company generates a free cash flow yield of 5.2%, which is healthy. Return on equity stands at -6.3%. The stock trades at 2.9x book value.
Over the past 10.8 years, a hypothetical investment of $100 in CDNA would have grown to $271, compared to $379 for the S&P 500. CDNA has returned 9.7% annualized vs 13.1% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CDNA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CDNA Crosses Below the Line?
Across 5 historical episodes, buying CDNA when it crossed below its 200-week moving average produced an average return of -42.8% after 12 months (median -31.0%), compared to +1.6% for the S&P 500 over the same periods. After 24 months, the average return was -63.8% vs +22.4% for the index.
Each line shows $100 invested at the moment CDNA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CDNA has crossed below its 200-week MA 5 times with an average 1-year return of +-46.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2015 | Jul 2015 | 2 | 9.1% | -31.1% | +148.9% |
| Jul 2015 | Aug 2015 | 5 | 9.2% | -29.5% | +162.2% |
| Sep 2015 | Oct 2017 | 107 | 83.6% | -40.6% | +150.7% |
| Jan 2022 | Jan 2022 | 4 | 6.6% | -71.2% | -56.1% |
| Feb 2022 | Nov 2025 | 197 | 86.4% | -59.1% | -55.0% |
| Average | 63 | — | +-46.3% | — |
Frequently Asked Questions
Is CDNA below its 200-week moving average?
No. CareDx, Inc. (CDNA) is currently 8.1% above its 200-week moving average of $15.87. It would need to fall to $15.87 to cross below the line.
What is CDNA's 200-week moving average price?
CareDx, Inc.'s 200-week moving average is $15.87 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CDNA drops below its 200-week moving average?
CDNA has crossed below its 200-week moving average 5 times in our data. The average one-year return after these crossings was -46.3%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 63 weeks on average.
Is CDNA a good value right now?
Here's what our data says about CDNA as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 34. Free cash flow yield is 5.2%. Return on equity is -6.3%. Price-to-book is 2.9x. This is not a buy or sell recommendation — always do your own research.
How does CDNA compare to the S&P 500?
Over the past 10.8 years, $100 invested in CDNA would have grown to $271, compared to $379 for the S&P 500. That's 9.7% annualized vs 13.1% for the index. CDNA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20